ArticleInternational journal of nephrology and renovascular disease2011
Diabetic microvascular complications: possible targets for improved macrovascular outcomes.
Article in International journal of nephrology and renovascular disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 17 citations in OpenAlex.
- Article
- Lipid Toxicity in the Cardiovascular-Kidney-Metabolic Syndrome (CKMS).Biomedicines · 2024Review
- The Diabetic Cardiorenal Nexus.International journal of molecular sciences · 2022Review
- Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review.Clinical kidney journal · 2016Article
- A cross-sectional assessment to detect type 2 diabetes with endothelial and autonomic nervous system markers using a novel system.Journal of diabetes and metabolic disorders · 2014Article
- Do biologic markers predict cardiovascular end points in diabetic end-stage renal disease? A prospective longitudinal study.Clinical kidney journal · 2013Article
- Role of single-pill combination therapy in optimizing blood pressure control in high-risk hypertension patients and management of treatment-related adverse events.Journal of clinical hypertension (Greenwich, Conn.) · 2012Review
- Epidemiology and management of hypertension in the Hispanic population: a review of the available literature.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The results of recent outcome trials challenge hypotheses that tight control of both glycohemoglobin and blood pressure diminishes macrovascular events and survival among type 2 diabetic patients. Relevant questions exist regarding the adequacy of glycohemoglobin alone as a measure of diabetes control. Are we ignoring mechanisms of vasculotoxicity (profibrosis, altered angiogenesis, hypertrophy, hyperplasia, and endothelial injury) inherent in current antihyperglycemic medications? Is the polypharmacy for lowering cholesterol, triglyceride, glucose, and systolic blood pressure producing drug interactions that are too complex to be clinically identified? We review angiotensin-aldosterone mechanisms of tissue injury that magnify microvascular damage caused by hyperglycemia and hypertension. Many studies describe interruption of these mechanisms, without hemodynamic consequence, in the preservation of function in type 1 diabetes. Possible interactions between the renin-angiotensin-aldosterone system and physiologic glycemic control (through pulsatile insulin release) suggest opportunities for further clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.